About Aqtual
Aqtual is a company based in San Francisco (United States) founded in 2017. Aqtual has raised $47 million across 2 funding rounds from investors including Yu Galaxy, Manta Ray and Genoa Ventures. The company has 29 employees as of December 31, 2024. Aqtual offers products and services including RA Blood Test and Epigenetics Catalog. Aqtual operates in a competitive market with competitors including Evergreen Nephrology, Pathalys, AdaptX, Specialty Networks and Bial, among others.
- Headquarter San Francisco, United States
- Employees 29 as on 31 Dec, 2024
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aqtual
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$47 M (USD)
in 2 rounds
-
Latest Funding Round
$31 M (USD), Series B
Jul 10, 2025
-
Investors
Yu Galaxy
& 4 more
-
Employee Count
29
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aqtual
Aqtual offers a comprehensive portfolio of products and services, including RA Blood Test and Epigenetics Catalog.
Guides therapy management for Rheumatoid Arthritis through biomarker identification.
Provides disease-specific targets from cell-free DNA for drug development.
People of Aqtual
Unlock access to complete
Funding Insights of Aqtual
Aqtual has successfully raised a total of $47M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $31 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aqtual
Aqtual has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Yu Galaxy, Manta Ray and Genoa Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in innovative founders by Yu Galaxy.
|
Locked | Locked | Locked | |
|
Early-stage ventures are targeted for investment by this VC fund.
|
Locked | Locked | Locked | |
|
Early-stage VC firm focused on life science startups
|
Locked | Locked | Locked |
Investor details for Aqtual
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aqtual
Investment portfolio details for Aqtual
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aqtual
Detailed financials for Aqtual
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aqtual Comparisons
Peer comparison for Aqtual
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aqtual
Aqtual operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evergreen Nephrology, Pathalys, AdaptX, Specialty Networks and Bial, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Chronic care management services for kidney diseases are provided.
|
|
| Locked | Locked | Locked |
Biotherapeutics for chronic kidney disease are developed and provided.
|
|
| Locked | Locked | Locked |
Clinical management solutions are provided for healthcare by AdaptX.
|
|
| Locked | Locked | Locked |
Specialty Networks is focused on supporting independent specialty healthcare providers.
|
|
| Locked | Locked | Locked |
Develops and commercializes pharmaceutical products through research and global distribution.
|
|
| Locked | Locked | Locked |
Chronic care management services are provided to patients.
|
Detailed competitors of Aqtual
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aqtual
Complete news archive for Aqtual
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aqtual
Aqtual was founded in 2017 and raised its 1st funding round 6 years after it was founded.
Aqtual is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Aqtual is a funded company, having raised a total of $47M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Aqtual is 29.
Aqtual was founded in 2017 and is headquartered in San Francisco, United States. Operations focus on the healthcare sector, where clinical product launching services are offered to support medical innovations. Chronic disease management solutions are developed to address ongoing patient needs, while diagnostic platform services enable efficient testing and analysis. The company serves providers and stakeholders in the diagnostic and therapeutic fields across the region.
Aqtual's top competitors include Evergreen Nephrology, Pathalys and AdaptX.
Aqtual offers RA Blood Test and Epigenetics Catalog.
Aqtual has 5 investors. Key investors include Yu Galaxy, Manta Ray, Genoa Ventures, Bold Capital Partners, and BOLD Longevity Growth.